MGNX vs XNCR
MGNX: Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms. XNCR: Xencor is a clinical-stage biopharma using proprietary protein engineering to develop next-generation bispecific antibodies for cancer and autoimmune conditions.
Side-by-side fundamentals
| Metric | MGNX | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $3.69 | $20.21 | |
| Market cap as of 2026-08-03 | $235M | $1.5B | |
| PEG as of 2026-08-03 | -0.14 | n/a | |
| Net margin as of 2026-08-03 | -44.8% | -177.1% | MGNX higher |
| Gross margin as of 2026-08-03 | +74.5% | n/a | |
| Operating margin as of 2026-08-03 | -40.5% | -222.4% | MGNX higher |
| ROE as of 2026-08-03 | -147.8% | -28.8% | XNCR higher |
| ROA as of 2026-08-03 | -28.4% | -20.5% | XNCR higher |
| Debt / equity as of 2026-08-03 | 3.24 | 0.21 | XNCR lower |
| Revenue growth (YoY) as of 2026-08-03 | +2.0% | -25.4% | MGNX higher |
| Revenue CAGR (3y) SEC XBRL | -0.5% | -8.6% | MGNX higher |
| Beta as of 2026-08-03 | 1.49 | 1.51 | |
| 1-year return as of 2026-07-31 close | +136.5% | +142.9% | XNCR higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.